Community Outreach, (928) 771-5686 | Jan 10, 2022
In November 2020, the U.S. Food and Drug Administration issued an Emergency Use Authorization to allow the use of monoclonal antibodies (MAB) for the treatment of mild to moderate symptoms of COVID-19.
Two COVID monoclonal antibody products – Regeneron and BAM/Ete – are not effective against the Omicron variant of the COVID-19 virus. Dignity Health, Yavapai Regional Medical Center (YRMC) is no longer administering Regeneron and BAM/Ete treatments based on current recommendations due to the high proportion of Omicron cases present in Arizona.
YRMC will continue to offer Sotrovimab COVID monoclonal antibody treatments, which have shown to be effective against the Omicron variant.
The supply of Sotrovimab is severely depleted and will be administered to only the highest risk patients based on availability.
What are the criteria for COVID MAB therapy (Sotrovimab)?
- Must be 60 years of age or older; and
- A positive test result for SARS CoV-2 viral testing (COVID-19) is required; and
- Must have mild to moderate symptoms for 10 days or less; and
- No new or increased oxygen requirement; and
- Must have either a severe underlying health condition or be immunocompromised.
Who cannot receive COVID MAB therapy (Sotrovimab)?
- Anyone still waiting for a COVID-19 test result.
- Anyone who has received a negative COVID-19 test result.
- People with symptoms for more than 10 days.
- New or increased oxygen requirement, hospitalized patients.
- People without an underlying health condition (your doctor can help you determine if you do or don’t have risk factors).
How do I schedule an appointment for COVID MAB therapy (Sotrovimab)?
- Call your doctor as soon as possible if you are sick and believe you qualify.
- An order must be sent by your physician to the Infusion Center at Dignity Health, Yavapai Regional Medical Center.
- A representative from YRMC will call you to schedule your appointment once the physician order has been received.